Stocks took off out of the gate this morning on reports on Chinese television that said a drug being tested by researchers at Zhejiang University in China was effective against the virus. That speculation got further traction on news that China had started a clinical trial to test Gilead Sciences(GILD) Remdesivir, an antiviral developed for Ebola […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
